Additional Preclinical Data to be Presented at the Fifth Joint Triennial Congress of ECTRIMS and ACTRIMS Further Elucidate the Anti-inflammatory Mechanism of COPAXONE® JERUSALEM--(BUSINESS WIRE)-- ...
PreCISe Data Presented at World Congress on Treatment and Research in Multiple Sclerosis JERUSALEM--(BUSINESS WIRE)--New data from PreCISe, in clinically isolated syndrome patients, have demonstrated ...
Approved in 1996, Copaxone® is the global market leader in the treatment of relapsing-remitting multiple sclerosis (RRMS) Ongoing, prospective, clinical trial follow-up reinforces the established ...
Verywell Health on MSN
How multiple sclerosis is treated
Medically reviewed by Brigid Dwyer, MD Key Takeaways Disease-modifying therapies slow down the progression of multiple ...
Copaxone (glatiramer acetate) may not be safe to receive while pregnant or breastfeeding. Certain factors, including the risks of fetal harm, may determine whether you can receive the drug during this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback